Genmab — Juli 2019
-
-
U.S. Food and Drug Administration has approved oral XPOVIO in combination with dexamethasone for the treatment of relapsed or refactory multiple myeloma in adult patients. Karyopharm expects XPOVIO to become commercially available in the U.S. on or before July 10, 2019.
-
Hvad mon det kommer til at betyde for Genmab?
-
ok
-
-
The news of the approval was clearly a surprise to investors, sending Karyopharm's stock shooting up about 40%. The FDA's final decision is at odds with that of the Oncologic Drug's Advisory Committee (ODAC), which had voted 8-5 against recommending approval and instead advocated waiting for results from the ongoing Phase III BOSTON trial.
-
The FDA granted accelerated approval to Karyopharm's application for Xpovio (selinexor) as a treatment for multiple myeloma (MM) in patients refractory to at least two proteasome inhibitors, two immunomodulators, and an anti-CD38 monoclonal antibody
-
At Medwatch skriver som de gør er fint nok - der er trods alt andre der læser med end os investorer, så når der er tale om dødelige bivirkninger, så må og skal det ud til alle. De skriver også at Janssen har udsendt deres materiale her i slutningen af Juni......hvem ved måske i forbindelse med MAIA godkendelsen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind